Biotherapeutic Conjugation Services
Biotherapeutics, represent a significant advancement in personalised medicine, offering targeted therapies for a wide range of diseases.
These biological products are engineered to interact with specific molecular targets associated with disease processes, providing high efficacy and reduced side effects compared to traditional therapies.
Antibody-drug conjugates (ADCs) are a groundbreaking class of biopharmaceuticals which combine the precise targeting capabilities of antibodies with the potent cell-killing activity of chemotherapy drugs. This union enables selective targeting of diseased cells whilst sparing healthy tissue, representing a powerful approach in the treatment of cancer and other serious conditions.
Biotherapeutics & Antibody Drug Conjugates (ADCs)
Our knowledge covers essential aspects such as conjugation chemistry, stoichiometry, and in vivo behaviour, guaranteeing consistent and reliable results.
Previous Projects
Nanoparticle-Antibody Conjugation for Drug Delivery
The project concentrated on optimising the conjugation of a nanoparticle-based delivery system with antibodies for use in targeted drug delivery. This innovative approach is designed to enhance the precision and efficacy of therapeutic delivery, minimising side effects and improving patient outcomes.
Doxorubicin-Peptide Conjugation for Academia
The project involved chemical modification of the chemotherapy drug doxorubicin to develop a targeted peptide-drug conjugate. The synthesis of this conjugate was successfully completed, and subsequent testing by the client yielded positive results.
MMAE Linker Screening for an Antibody-Drug Conjugate
The project focused on preparation of various linker chemistries for their antibody-drug conjugate (ADC) connected to the drug monomethyl auristatin E (MMAE). The customer's objective was to evaluate the stability and efficacy of different linkers to optimise the therapeutic delivery and effectiveness of the ADC in targeting cancer cells.